Clinical Insights
A strong end point and trial design is critical for the success of late-stage biologics. PHASE-XS surfaces clinically essential information on pipeline products for researchers with substantial R&D investments.
Proprietary database
PHASE-XS
The market solution for biologics & biosimilars
A robust clinical-trials and commercial analytics database covering late-stage (Phase I–IV) biologics and biosimilar candidates.
35+
Profiling parameters
I–IV
Trial phase coverage
100%
Late-stage focus
Biologics & Biosimilars
Therapeutic scope
About Phase-XS
Late-stage clinical & commercial analytics, under one umbrella.
Developed by our team of consultants and industry experts, PHASE-XS is a proprietary database of Coherent Market Insights that sheds light on potential developments for late-stage biologics and biosimilar candidates.
Beyond freely accessible clinical information, PHASE-XS profiles each trial across 35+ parameters — combining clinical and analytical insights on pipeline products in a single, navigable view.
Parameter coverage
Every trial, profiled across 35+ data points
Four pillars
Built for product, strategy, and commercial teams.
PHASE-XS combines four intelligence layers so cross-functional teams make late-stage decisions with the same evidence base.
Market Insights
Key market signals that shape the therapeutic segment — future competition, demand dynamics, and emerging trends — distilled into actionable intelligence for product teams.
Competitive Intelligence
Know your competitor’s activity and product roadmap. PHASE-XS surfaces strengths, weaknesses, and white-space opportunities through scrupulous analysis from our industry experts.
Data Analytics
User-friendly representation is what we strive for our PHASE-XS subscribers. Coherent Market Insights delivers data in a format that lets you run analysis and get outcomes in seconds.
Talk to our biologics team
Ready to see Phase-XS in your therapeutic area?
Get a personalized walkthrough of the database, including coverage of your pipeline competitors and white-space opportunities.